A Study on the Application and Use of Artificial Intelligence to Support Drug Development.

Journal: Clinical therapeutics
Published Date: Jun 24, 2019

Abstract

PURPOSE: The Tufts Center for the Study of Drug Development (CSDD) and the Drug Information Association (DIA) in collaboration with 8 pharmaceutical and biotechnology companies conducted a study examining the adoption and effect of artificial intelligence (AI), such as machine learning, on drug development. The study was conducted to clarify and understand AI adoption across the industry and to gather detailed insights into the spectrum of activities included in the definition of AI. The study investigated and identified analytical platforms and innovations across pharmaceutical and biotechnology companies currently being used or planned for in the future.

Authors

  • Mary Jo Lamberti
    Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, MA, USA. Electronic address: mary_jo.lamberti@tufts.edu.
  • Michael Wilkinson
    Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, MA, USA.
  • Bruce A Donzanti
    Global Pharmacovigilance Innovation Policy, Genentech Inc, South San Francisco, CA, USA.
  • G Erich Wohlhieter
    Digital Health and Innovation, Amgen, Thousand Oaks, CA, USA.
  • Sudip Parikh
    Drug Information Association of the Americas, Washington, DC, USA.
  • Robert G Wilkins
    QPS Consulting LLC, Ashburn, VA, USA.
  • Ken Getz
    Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, MA, USA.

Keywords

External Resources

Popular Topics
Recent Journals